Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod (NCT06529406)
Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod (COAST: CD20 and Ozanimod Sequencing Trial)
🩺 Plain-English Summary (8th-Grade Level)
A multi-center pilot study to evaluate safety and efficacy of ozanimod as de-escalation therapy in clinically stable MS patients previously treated with anti-CD20 therapy.
Who can join: Review the eligibility criteria below.
Location: University of Colorado Anschutz Medical Campus — Aurora, Colorado
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- University of Colorado Anschutz Medical Campus — Aurora, Colorado
- Cleveland Clinic — Las Vegas, Nevada
- Cleveland Clinic — Cleveland, Ohio
📞 Contact the Study Coordinator
Phone: (303) 724-8249
Email: enrique.alvarez@cuanschutz.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Relapsing Multiple Sclerosis
- A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS) — Fullerton, California
- A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone) — Cullman, Alabama
- Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis — Maitland, Florida
- Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2) — Phoenix, Arizona
- A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis. — Birmingham, Alabama
- A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) — Birmingham, Alabama
Explore by condition: All Relapsing Multiple Sclerosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.